Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Adverse reactions of dimethyl sulfoxide in humans: a systematic review [version 2; peer review: 2 approved with reservations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pragmatic Home-Based Exercise after Total Hip Arthroplasty - Silkeborg: Protocol for a prospective cohort study (PHETHAS-1)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Head models of healthy and depressed adults for simulating the electric fields of non-invasive electric brain stimulation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Recent advances in understanding and managing contact dermatitis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs.

OriginalsprogEngelsk
TidsskriftF1000Research
Vol/bind6
Sider (fra-til)e444
ISSN2046-1402
DOI
StatusUdgivet - 2017

ID: 52166945